Table 6.

In each of the 11 experiments, 20 top-ranked significant treatments with compounds whose sets of upregulated genes significantly overlap with the set of genes selected for each experiment were identified. Therefore, treatment with the following compounds is most frequently ranked within the top 20.

Exp.	#	(i)	(ii)	(iii)
1	(232)			16/166
	[191]			$2.16\times {10}^7$
2	(711)	23/125	30/163
	[450]	$1.58\times {10}^7$	$1.11\times {10}^9$
3	(747)		34/163
	[559]		$6.14\times {10}^{12}$
4	(441)	15/125
	[85]	$2.12\times {10}^4$
5	(123)
	[116]
6	(292)		18/163
	[190]		$2.46\times {10}^7$
7	(246)
	[145]
8	(873)	22/125		31/166
	[69]	$6.56\times {10}^5$		$1.80\times {10}^7$
9	(119)			8/166
	[0]			$1.95\times {10}^2$
10	(104)
	[0]
11	(120)
	[33]

(i) LJP005_A375_24H-GDC-0980-0.37; (ii) LJP005_HEPG2_24H-PLX-4720-10; and (iii) LJP007_MCF7_24H-dinaciclib-0.12 #: (numbers): genes; [numbers]: compounds. Upper rows in each exp: OL, overlaps (the number of genes coinciding with the genes selected for each experiment)/(genes listed in Enrichr in each category). Lower rows in each exp: adjusted P-values provided by Enrichr.